Almirall stock gains on half-year profit and sales growth

Published on 09/04/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock advances with half-year profit up 49.4 percent and revenue at EUR 580.7 million. The latest market data also point to a market value above EUR 3 billion.

Aquarellmalerei der Barcelona-Skyline mit modernen Bürotürmen im Mittelmeerlicht — Almirall S.A. (ES0157097017) präsentiert die Barcelona-Skyline als Aquarell, Heimatstadt des IBEX-35-Pharmaunternehmens Almirall, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) advances as the Barcelona-listed drugmaker reports half-year net profit of EUR 39.6 million, up 49.4 percent from a year earlier, while revenue reached EUR 580.7 million in the first half of 2026. The latest market snapshot also shows a market capitalization of USD 3.061 billion and a previous close of 14.07 on September 3, 2026.

Half-year figures stay firm

According to Democrata, Almirall said net profit in the first half of 2026 rose to EUR 39.6 million from the same period a year earlier, a gain of 49.4 percent. The same report puts first-half revenue at EUR 580.7 million, while the company also communicated the figures to the CNMV.

That revenue base matters because it frames the profit move: EUR 39.6 million of net profit on EUR 580.7 million of sales gives the stock a clear earnings anchor, not just a trading move.

Market value above 3 billion

Yahoo Finance shows Almirall at a market capitalization of USD 3.061 billion and a previous close of 14.07 on September 3, 2026. Its quote snapshot also lists Q2 FY26 revenue of USD 310.31 million and earnings of USD 24.25 million, giving investors a second dated reference point for the current reporting year.

The comparison is straightforward: first-half net profit of EUR 39.6 million is 49.4 percent higher year on year, and Q2 FY26 revenue of USD 310.31 million sits alongside a profit margin of 7.82 percent in the quote data.

Go deeper

Almirall half-year numbers and investor details

The company reported first-half profit and revenue growth, and the investor page remains the central place for updates.

Almirall coverage Investor Relations

Dermatology remains central

Almirall's dermatology focus is the business backdrop behind the half-year numbers, with the listed group based in Barcelona and active across prescription skin treatments. The current quote data and the half-year figures together show why the market still reads the story through sales, margin and profit.

Stock and valuation

As of September 3, 2026, the last quoted close was 14.07, and the market capitalization stood at USD 3.061 billion. That leaves Almirall stock trading with a clear earnings story for 2026 rather than a pure momentum move.